A commonly used diabetes medication is demonstrating potential in reversing liver scarring caused by fatty liver disease. Researchers have found the drug, metformin, significantly improved fibrosis—the development of scar tissue—in patients with non-alcoholic steatohepatitis (NASH). This condition, a severe form of fatty liver disease, can lead to cirrhosis and liver failure. The study suggests metformin may reduce inflammation and collagen production, key factors in scar tissue formation. While further research is needed, these findings offer a potential new treatment avenue for the millions affected by NASH, currently lacking specific approved therapies. This drug repurposing approach could expedite treatment availability and reduce development costs compared to creating new drugs. Experts caution that metformin isn't a universal solution and lifestyle changes remain crucial.